Insulet (NASDAQ:PODD) Price Target Cut to $375.00 by Analysts at The Goldman Sachs Group

Key Points

• The Goldman Sachs Group has reduced its price target for Insulet (NASDAQ:PODD) from $399.00 to $375.00, while maintaining a "buy" rating on the stock, suggesting a potential upside of 20.21% from its current price.
• Insulet reported earnings of $1.17 per share for the last quarter, exceeding the consensus estimate of $0.92, alongside revenues of $649.10 million, which were above expected levels.
• Insider selling was noted with senior vice president Prem Singh and another executive disposing of shares; Singh's sale represented a 16.58% decrease in their position in the company.

Insulet (NASDAQ:PODD - Get Free Report) had its target price reduced by equities researchers at The Goldman Sachs Group from $399.00 to $375.00 in a research report issued on Wednesday,MarketScreener reports. The brokerage presently has a "buy" rating on the medical instruments supplier's stock. The Goldman Sachs Group's price objective points to a potential upside of 20.21% from the company's current price.

Several other equities analysts have also weighed in on PODD. Wall Street Zen upgraded shares of Insulet from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Jefferies Financial Group restated a "buy" rating on shares of Insulet in a research note on Thursday, August 7th. Truist Financial began coverage on Insulet in a research report on Monday, June 16th. They set a "buy" rating and a $365.00 target price on the stock. Royal Bank Of Canada increased their price target on Insulet from $330.00 to $350.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Finally, Barclays upped their target price on Insulet from $266.00 to $300.00 and gave the company an "equal weight" rating in a research report on Thursday, August 21st. Sixteen research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, Insulet currently has a consensus rating of "Moderate Buy" and a consensus price target of $345.47.

Insulet Price Performance

PODD stock opened at $311.96 on Wednesday. The stock's 50 day moving average price is $320.07 and its 200 day moving average price is $297.80. The firm has a market cap of $21.96 billion, a P/E ratio of 94.68, a PEG ratio of 2.58 and a beta of 1.36. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. Insulet has a 1 year low of $225.37 and a 1 year high of $353.50.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.25. The business had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business's revenue was up 32.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, sell-side analysts expect that Insulet will post 3.92 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Insulet news, SVP Prem Singh sold 687 shares of the company's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Laetitia Cousin sold 797 shares of the business's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares of the company's stock, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.39% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Curi Capital LLC grew its holdings in Insulet by 0.8% during the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier's stock worth $1,365,000 after acquiring an additional 36 shares during the period. Evelyn Partners Investment Management Services Ltd lifted its position in shares of Insulet by 28.7% during the 2nd quarter. Evelyn Partners Investment Management Services Ltd now owns 175 shares of the medical instruments supplier's stock valued at $55,000 after acquiring an additional 39 shares during the last quarter. Camarda Financial Advisors LLC grew its holdings in shares of Insulet by 0.5% in the 2nd quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier's stock worth $2,304,000 after acquiring an additional 40 shares during the last quarter. Sequoia Financial Advisors LLC lifted its holdings in shares of Insulet by 2.3% during the second quarter. Sequoia Financial Advisors LLC now owns 2,017 shares of the medical instruments supplier's stock valued at $634,000 after purchasing an additional 45 shares during the last quarter. Finally, Nissay Asset Management Corp Japan ADV increased its stake in Insulet by 0.6% in the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier's stock worth $2,222,000 after purchasing an additional 48 shares in the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.